Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

NCT00030667 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

100

Enrollment

NIH

Sponsor class

Conditions

Childhood Desmoplastic Small Round Cell Tumor
Childhood Synovial Sarcoma
Gastrointestinal Stromal Tumor
Lung Metastases
Recurrent Childhood Soft Tissue Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Neuroblastoma
Recurrent Osteosarcoma

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)